Page last updated: 2024-08-16

rivastigmine and Anxiety Neuroses

rivastigmine has been researched along with Anxiety Neuroses in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anzures-Cabrera, J; Higgins, JP; Sarpatwari, A	1
Retz, W; Retz-Junginger, P; Rösler, M; Supprian, T; Wobrock, T	1

Other Studies

2 other study(ies) available for rivastigmine and Anxiety Neuroses

Article	Year
Expressing findings from meta-analyses of continuous outcomes in terms of risks. Statistics in medicine, 2011, Nov-10, Volume: 30, Issue:25 Topics: Anxiety Disorders; Behavior Therapy; Computer Simulation; Data Interpretation, Statistical; Dementia; Humans; Meta-Analysis as Topic; Neuroprotective Agents; Odds Ratio; Phenylcarbamates; Randomized Controlled Trials as Topic; Risk; Rivastigmine; Sample Size	2011
[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Fortschritte der Neurologie-Psychiatrie, 2003, Volume: 71, Issue:4 Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Female; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine	2003

Article

Year

Expressing findings from meta-analyses of continuous outcomes in terms of risks.

Statistics in medicine, 2011, Nov-10, Volume: 30, Issue:25

Topics: Anxiety Disorders; Behavior Therapy; Computer Simulation; Data Interpretation, Statistical; Dementia; Humans; Meta-Analysis as Topic; Neuroprotective Agents; Odds Ratio; Phenylcarbamates; Randomized Controlled Trials as Topic; Risk; Rivastigmine; Sample Size

2011

[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].

Fortschritte der Neurologie-Psychiatrie, 2003, Volume: 71, Issue:4

Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Female; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine

2003